Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matt Kalaycio

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Blood Advances|June 23, 2023
Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease preventionBetty K Hamilton, Lisa A Rybicki, Hong Li, et al.
Bone Marrow Transplantation|October 31, 2018
Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantationSagar S Patel, Lisa A Rybicki, Donna Corrigan, et al.
Hematology/Oncology and Stem Cell Therapy|December 28, 2019
Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantationSagar S Patel, Lisa A Rybicki, Melissa Yurch, et al.
Leukemia Research|April 30, 2010
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemiaAnjali S Advani, Ramon Tiu, Yogen Saunthararajah, et al.
The Journal of Clinical Investigation|January 27, 2015
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromesYogen Saunthararajah, Mikkael Sekeres, Anjali Advani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2017
Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized StudyDebbie Bates, Brian Bolwell, Navneet S Majhail, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2017
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic SyndromeMoaath Mustafa Ali, Donna M Abounader, Lisa A Rybicki, et al.
Plos One|August 21, 2012
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosisFabiola Traina, Valeria Visconte, Anna M Jankowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid LeukemiaAnjali S Advani, Brenda Cooper, Valeria Visconte, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Blood Advances|June 23, 2023
Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease preventionBetty K Hamilton, Lisa A Rybicki, Hong Li, et al.
Bone Marrow Transplantation|October 31, 2018
Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantationSagar S Patel, Lisa A Rybicki, Donna Corrigan, et al.
Hematology/Oncology and Stem Cell Therapy|December 28, 2019
Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantationSagar S Patel, Lisa A Rybicki, Melissa Yurch, et al.
Leukemia Research|April 30, 2010
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemiaAnjali S Advani, Ramon Tiu, Yogen Saunthararajah, et al.
The Journal of Clinical Investigation|January 27, 2015
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromesYogen Saunthararajah, Mikkael Sekeres, Anjali Advani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2017
Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized StudyDebbie Bates, Brian Bolwell, Navneet S Majhail, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2017
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic SyndromeMoaath Mustafa Ali, Donna M Abounader, Lisa A Rybicki, et al.
Plos One|August 21, 2012
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosisFabiola Traina, Valeria Visconte, Anna M Jankowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid LeukemiaAnjali S Advani, Brenda Cooper, Valeria Visconte, et al.
Pageof 13